Scancell Holdings (FRA:SCP) Institutional Ownership: 1.51% (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:SCP Scancell Holdings PLC FRA:SCP
23 GF Score
Price €0.17
! 2 Warning Signs
View Full Analysis

What is Scancell Holdings Institutional Ownership?

Scancell Holdings FRA:SCP +41.32% 23 Institutional Ownership is 1.51% as of Jul. 19, 2026. GuruFocus rates FRA:SCP with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Scancell Holdings's institutional ownership is 1.51%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Scancell Holdings's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Scancell Holdings's Float Percentage Of Total Shares Outstanding is 0.00%.

Scancell Holdings Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Scancell Holdings's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scancell Holdings Institutional Ownership Chart

Scancell Holdings Historical Data

The historical data trend for Scancell Holdings can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 1.51 1.51 1.52 1.52 1.51 1.51 1.51 1.51 1.51 1.51
FRA:SCP
23GF Score
Scancell Holdings PLC FRA:SCP
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scancell Holdings Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 1.51% mean?
Scancell Holdings (FRA:SCP) has a Institutional Ownership of 1.51% as of Jul. 19, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Scancell Holdings and its competitors.
Is Scancell Holdings' Institutional Ownership too high?
Scancell Holdings' current Institutional Ownership is 1.51%. Overall, Scancell Holdings has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' Institutional Ownership compare to VRTX and REGN?
Scancell Holdings' Institutional Ownership of 1.51% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Scancell Holdings and its competitors. Scancell Holdings's current Institutional Ownership is 1.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (FRA:SCP) has a current Institutional Ownership of 1.51%. The current Institutional Ownership is 1.51%. Scancell Holdings' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Scancell Holdings (FRA:SCP), the current Institutional Ownership is 1.51% as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scancell Holdings Business Description

Other Exchanges SCNLF:USASCLP:UK
Address Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
23GF Score

Get the complete analysis for FRA:SCP

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.17
Price